Crystalline And Amorphous Forms Of A Beta-Arrestin Effector

Abstract

The present disclosure provides novel crystalline forms of a compound that acts as a β-arrestin effector, processes for preparing novel crystalline and amorphous forms of a compound that acts as a β-arrestin effector and uses thereof.

1 - 42 . (canceled) 
     
     
         43 . A process for preparing a crystalline form of a peptide having a sequence of SEQ. ID. NO.1, comprising crystallizing SEQ. ID. NO. 1 to form a crystalline form of a peptide having a sequence of SEQ. ID. NO. 1. 
     
     
         44 . The process of  claim 43 , wherein the crystallizing comprises dissolving peptide in an aqueous solution and crystallizing the peptide to form the crystalline form therefrom. 
     
     
         45 . The process of  claim 44 , wherein the aqueous solution is deionized water. 
     
     
         46 . The process of  claim 44 , wherein the aqueous solution consists of deionized water. 
     
     
         47 . The process of  claim 44 , wherein the process further comprises precipitating the peptide after dissolving the peptide in the aqueous solution. 
     
     
         48 . The process of  claim 47 , wherein the precipitating comprises heating the aqueous solution and cooling the aqueous solution to ambient temperature to precipitate the peptide in the crystalline form. 
     
     
         49 . The process of  claim 48 , wherein the process further comprises cooling the aqueous solution to a temperature of about 0 to about 5° C. to precipitate the peptide in the crystalline form. 
     
     
         50 . The process of  claim 43 , further comprising lyophilizing the crystalline form. 
     
     
         51 . A pharmaceutical composition comprising a crystalline form of a peptide having a sequence of SEQ. ID. NO.1. 
     
     
         52 . A method of treating a cardiovascular or a cardiorenal disorder comprising administering to a patient in need thereof the pharmaceutical composition of  claim 51 . 
     
     
         53 . A crystalline form of a peptide having a sequence of SEQ. ID. NO. 1. 
     
     
         54 . The crystalline form of  claim 53 , characterized by an X-ray powder diffraction pattern comprising a peak at about 18.5±0.5 degrees 2θ. 
     
     
         55 . The crystalline form of  claim 53 , characterized by an X-ray powder diffraction pattern comprising a peak at about 10.1±0.5 degrees 2θ. 
     
     
         56 . The crystalline form of  claim 53 , characterized by an X-ray powder diffraction pattern comprising a peak at about 8.2±0.5 degrees 2θ. 
     
     
         57 . The crystalline form of  claim 53 , characterized by an X-ray powder diffraction pattern comprising a peak at about 20.2±0.5 degrees 2θ. 
     
     
         58 . The crystalline form of  claim 53 , characterized by an X-ray powder diffraction pattern comprising a peak at about 24.4±0.5 degrees 2θ. 
     
     
         59 . The crystalline form of  claim 53 , characterized by an X-ray powder diffraction pattern comprising peaks at about 18.5, and at about 10.1±0.5 degrees 2θ. 
     
     
         60 . The crystalline form of  claim 53 , characterized by an X-ray powder diffraction pattern comprising peaks at about 10.1, and at about 8.2±0.5 degrees 2θ. 
     
     
         61 . The crystalline form of  claim 53 , characterized by an X-ray powder diffraction pattern comprising peaks at about 8.2, and at about 20.2±0.5 degrees 2θ. 
     
     
         62 . The crystalline form of  claim 53 , characterized by an X-ray powder diffraction pattern comprising peaks at about 20.2, and at about 10.1±0.5 degrees 2θ.